Navigation Links
ViroPharma Incorporated Honored by the National Organization for Rare Disorders
Date:5/18/2009

EXTON, Pa., May 18 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) was honored with a Corporate Award at the National Organization for Rare Disorders (NORD) Annual Gala for its work in bringing Cinryze(TM) (C1 esterase inhibitor (human)) to market for a rare and devastating disorder -- hereditary angioedema (HAE).

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of swelling affecting the larynx, abdomen, face, extremities and urogenital tract. There are estimated to be at least 4,600 people with HAE in the United States.

"We are honored to be recognized by NORD for our work in bringing Cinryze to HAE patients in the U.S.," said Vincent Milano, ViroPharma's president and chief executive officer, "but what is even more gratifying for everyone at ViroPharma is making a difference in the lives of HAE patients who have literally been waiting for decades for this therapy."

Cinryze (C1 esterase inhibitor (human)) was approved by the U.S. Food and Drug Administration in October 2008 for routine prophylaxis against HAE attacks in adults and adolescents. In February 2009, ViroPharma was granted priority review of a supplemental Biologics License Application for Cinryze for the treatment of acute attacks of HAE. If approved, Cinryze may be the first C1 esterase inhibitor available for the acute treatment for this condition. ViroPharma's Prescription Drug User Fee Act (PDUFA) date for the use of Cinryze for acute attacks in patients with HAE is June 3, 2009.

The NORD Gala is an annual event at which researchers and others are honored for significant achievements to im
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. ViroPharma To Acquire Lev Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Bellingham, WA (PRWEB) July 29, 2014 ... manipulation of the brain that are driving a revolution ... a new peer-reviewed journal published by SPIE, ... The first issue coincides with the launch of the ... section features articles that lay out a vision for ...
(Date:7/29/2014)... JOLLA, Calif. , July 29, 2014 ... diagnostic and therapeutic company focused on extending the healthy, ... hired Franz Och , Ph.D., an expert in ... Data Scientist. Och comes to HLI from Google where ... Google Translate. He will report directly to HLI Co-Founder ...
(Date:7/29/2014)... Tough, ultralight foam of atom-thick sheets can be made ... invented at Rice University. , In microscopic images, ... with floors and walls that reinforce each other. The ... and walls of graphene oxide that self-assemble with the ... researchers say the foam could find use in structural ...
(Date:7/29/2014)... ELLICOTT CITY, Md. , July 29, 2014 ... has announced a new and updated program for ... October 10 – 12, 2014 in Amelia ... sponsors, CROs, sites and investigators remains unchanged, however, ... more purposeful exchange and networking opportunity among all ...
Breaking Biology Technology:SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3Tough foam from tiny sheets 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3
... 26 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today ... the addition of two new members. Appointed to the company,s ... Chatfield. With their addition, the company board now has eight ... of the U. S. Selective Service System from November of ...
... Pa., Oct. 26 Cadient Group , ... today announced that it has been recognized as one of ... the Greater Philadelphia region for the second consecutive year. ... during the five year period from 2004-2008. Cadient Group ...
... , ... blue dye test alternative using innovative laser technology has been installed at ... processes. Bayer China has acquired Sepha ’s ‘BlisterScan’ machines for non-destructive leak testing ... ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Expands Board of Directors 2Cadient Group Ranks as Deloitte Fast 50 Company for Greater Philadelphia Region for Second Consecutive Year 2Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 2Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 3
(Date:7/30/2014)... about what they eat, the Food and Drug Administration ... Nutrition Facts label found on nearly every food product ... Engineering News (C&EN), the weekly news magazine of ... and the fight that has ensued. , Britt Erickson, ... the Nutrition Facts label has remained largely the same ...
(Date:7/30/2014)... major interest in neuroscience. A large number of ... of Wallerian degeneration: transcription factor activation, immune response, ... responses in the distal segment of the sciatic ... in gene expression between the proximal and distal ... from Nantong University, China used microarrays to analyze ...
(Date:7/30/2014)... Calif. , July 30, 2014 ... with the United States Air Force Research Laboratory ... by Binghamton University to ... performance monitoring (HPM). The $425,000 project, with contributions ... packaging firm i3 Electronics, Inc. ( Endicott, ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... Nature Genetics, is based on data from more than ... but also discovered ten new genes. Altogether they explain ... The analysis produced some biologically insightful findings. Several ... let-7, which affects the regulation of other genes. This ...
... University of Leicester engineer has won a share of ... cancer. In an unusual move, Dr. Declan Bates, ... the University of Leicester, is co-recipient of 1,068,000 in ... the Engineering and Physical Sciences Research Council (EPSRC) and ...
... to determine if global warming threatens the polar bear population ... listing the polar bear as an endangered species, according to ... journal of the Institute for Operations Research and the Management ... ordered the Interior Department to decide by May 15 whether ...
Cached Biology News:How body size is regulated 2Engineer to spearhead research into cell metabolism and medical injuries 2Federal polar bear research critically flawed, says study in INFORMS journal 2
... is an aqueous solution that contains a ... chemicals in a saline solution, pH 6.5 ... 0.02% methylisothiazolone and 0.02% bromonitrodioxane as a ... diluent and stabilizer for biologically active components ...
... clarification reagent; Ideal for clarifying many ... proteins, nucleic acids, & proteoglycans; Contains ... improves downstream processing; Utilizes a reagent ... supplied as a suspension in saline; ...
... StabilGuard Biomolecule Stabilizer is a bovine ... It is an aqueous solution that contains ... buffered saline), pH 6.6 - 7.2, and ... product maintains the activity of antibodies and ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
Biology Products: